Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 3—March 2006
Research

West Nile Virus Infections Projected from Blood Donor Screening Data, United States, 2003

Edward L. Murphy*†Comments to Author , David J. Wright‡, Brian S. Custer*, Leslie H. Tobler*, Susan L. Stramer§, Steven H. Kleinman*‡¶, Harry E. Prince#, Celso Bianco**, Gregory Foster§, Lyle R. Petersen††, George Nemo‡‡, and Simone A. Glynn‡
Author affiliations: *Blood Systems Research Institute, San Francisco, California, USA; †University of California, San Francisco, California, USA; ‡Westat, Rockville, Maryland, USA; §American Red Cross National Testing and Reference Laboratories, Gaithersburg, Maryland, USA; ¶University of British Columbia, Victoria, British Columbia, Canada; #Focus Diagnostics, Cypress, California, USA; **America's Blood Centers, Washington DC, USA; ††Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; ‡‡National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA

Main Article

Table

Estimated WNV seasonal incidence and related measures of WNV infection for each state and entire United States, 2003*

State No. MP-NAT–positive donations, 4-mo period No. donations, 4-mo period Estimated WNV seasonal incidence, % (95% CI) Midyear population estimate† Estimated no. infections Neuroinvasive cases reported to CDC‡
Alabama 3 48,044 0.12 (0.00–0.27) 4,500,752 5,336 25
Alaska 0 8,444 0.00 (0.00–0.00) 648,818 0 0
Arizona 2 86,157 0.04 (0.00–0.10) 5,580,811 2,291 7
Arkansas 1 49,750 0.04 (0.00–0.12) 2,725,714 1,050 23
California 2 394,470 0.01 (0.00–0.02) 35,484,453 3,231 2
Colorado 157 65,739 4.33 (1.83–6.83) 4,550,688 197,028 621
Connecticut 1 52,410 0.03 (0.00–0.10) 3,483,372 1,121 12
Delaware 3 19,853 0.28 (0.00–0.63) 817,491 2,268 12
District of Columbia 0 3,055 0.00 (0.00–0.00) 563,384 0 3
Florida 6 248,198 0.05 (0.00–0.09) 17,019,068 7,677 61
Georgia 6 118,981 0.09 (0.00–0.18) 8,684,715 7,803 27
Hawaii 0 16,981 0.00 (0.00–0.00) 1,257,608 0 0
Idaho 0 23,204 0.00 (0.00–0.00) 1,366,332 0 0
Illinois 15 236,926 0.11 (0.03–0.20) 12,653,544 14,399 30
Indiana 4 111,090 0.06 (0.00–0.14) 6,195,643 3,944 15
Iowa 6 89,649 0.12 (0.00–0.23) 2,944,062 3,476 81
Kansas 70 59,673 2.13 (0.85–3.42) 2,723,507 58,136 89
Kentucky 3 68,674 0.08 (0.00–0.18) 4,117,827 3,298 11
Louisiana 6 56,284 0.19 (0.00–0.38) 4,496,334 8,649 101
Maine 0 24,968 0.00 (0.00–0.00) 1,305,728 0 12
Maryland 7 75,403 0.17 (0.01–0.33) 5,508,909 9,418 49
Massachusetts 0 65,914 0.00 (0.00–0.00) 6,433,422 0 12
Michigan 7 174,776 0.07 (0.01–0.14) 10,079,985 7,122 14
Minnesota 22 114,571 0.35 (0.11–0.59) 5,059,375 17,589 48
Mississippi 6 47,980 0.23 (0.01–0.45) 2,881,281 6,548 34
Missouri 9 124,644 0.13 (0.02–0.24) 5,704,484 7,342 39
Montana 8 19,984 0.76 (0.08–1.43) 917,621 6,956 75
Nebraska 161 61,516 4.87 (2.06–7.68) 1,739,291 84,648 194
Nevada 1 32,651 0.06 (0.00–0.17) 2,241,154 1,267 2
New Hampshire 0 24,595 0.00 (0.00–0.00) 1,287,687 0 2
New Jersey 9 98,008 0.17 (0.02–0.31) 8,638,396 14,269 21
New Mexico 10 25,130 0.73 (0.12–1.34) 1,874,614 13,701 74
New York 10 245,357 0.07 (0.01–0.13) 19,190,115 13,774 57
North Carolina 1 146,807 0.01 (0.00–0.04) 8,407,248 1,087 16
North Dakota 30 13,971 4.14 (1.40–6.88) 633,837 26,264 94
Ohio 13 214,819 0.11 (0.02–0.19) 11,435,798 12,112 84
Oklahoma 23 98,287 0.43 (0.13–0.73) 3,511,532 15,196 56
Oregon 1 72,337 0.03 (0.00–0.08) 3,559,596 966 0
Pennsylvania 14 255,806 0.10 (0.02–0.17) 12,365,455 12,010 145
Rhode Island 0 580 0.00 (0.00–0.00) 1,076,164 0 5
South Carolina 0 70,369 0.00 (0.00–0.00) 4,147,152 0 3
South Dakota 46 20,430 4.02 (1.50–6.54) 764,309 30,716 151
Tennessee 4 88,532 0.08 (0.00–0.17) 5,841,748 4,797 21
Texas 80 309,469 0.48 (0.19–0.77) 22,118,509 106,013 431
Utah 0 35,448 0.00 (0.00–0.00) 2,351,467 0 0
Vermont 0 16,616 0.00 (0.00–0.00) 619,107 0 0
Virginia 1 77,634 0.02 (0.00–0.07) 7,386,330 1,623 19
Washington 0 93,469 0.00 (0.00–0.00) 6,131,445 0 0
West Virginia 1 25,560 0.07 (0.00–0.23) 1,810,354 1,342 1
Wisconsin 4 142,456 0.05 (0.00–0.11) 5,472,299 2,863 7
Wyoming 17 9,904 3.48 (0.94–6.02) 501,242 17,439 92
Total 770 4,585,573 0.25 (0.11–0.39) 290,809,777 735,000 (322,000–1,147,000)§ 2,866

*WNV, West Nile virus; MP-NAT, minipool-nucleic acid amplification testing; CI, confidence intervals.
†US Census Bureau (22).
‡Source: Centers for Disease Control and Prevention (23).
§Confidence intervals.

Main Article

References
  1. Petersen  LR, Marfin  AA, Gubler  DJ. West Nile virus. JAMA. 2003;290:524–8. DOIPubMedGoogle Scholar
  2. Petersen  LR, Hayes  EB. Westward ho?—The spread of West Nile virus. N Engl J Med. 2004;351:2257–9. DOIPubMedGoogle Scholar
  3. Petersen  LR, Marfin  AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137:173–9.PubMedGoogle Scholar
  4. Watson  JT, Pertel  PE, Jones  RC, Siston  AM, Paul  WS, Austin  CC, Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med. 2004;141:360–5.PubMedGoogle Scholar
  5. Gea-Banacloche  J, Johnson  RT, Bagic  A, Butman  JA, Murray  PR, Agrawal  AG. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med. 2004;140:545–54.PubMedGoogle Scholar
  6. Tsai  TF, Popovici  F, Cernescu  C, Campbell  GL, Nedelcu  NI. West Nile encephalitis epidemic in southeastern Romania. Lancet. 1998;352:767–71. DOIPubMedGoogle Scholar
  7. Mostashari  F, Bunning  ML, Kitsutani  PT, Singer  DA, Nash  D, Cooper  MJ, Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001;358:261–4. DOIPubMedGoogle Scholar
  8. Centers for Disease Control and Prevention. Provisional surveillance summary of the West Nile Virus epidemic—United States, January–November 2002. MMWR Morb Mortal Wkly Rep. 2002;51:1129–33.PubMedGoogle Scholar
  9. Biggerstaff  BJ, Petersen  LR. Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion. 2002;42:1019–26. DOIPubMedGoogle Scholar
  10. Pealer  LN, Marfin  AA, Petersen  LR, Lanciotti  RS, Page  PL, Shamer  SL, ; West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236–45. DOIPubMedGoogle Scholar
  11. Dodd  RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med. 2003;349:1205–6. DOIPubMedGoogle Scholar
  12. Centers for Disease Control and Prevention. Update: detection of West Nile virus in blood donations—United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:916–9.PubMedGoogle Scholar
  13. Stramer  SL, Glynn  SA, Kleinman  SH, Strong  DM, Caglioti  S, Wright  DJ, ; NHLBI-REDS NAT Study Group. Detection of HIV-1 and HCV infections among antibody-negative US blood donors by nucleic acid amplification testing. N Engl J Med. 2004;351:760–8. DOIPubMedGoogle Scholar
  14. Kleinman  S, Glynn  SA, Busch  M, Todd  D, Powell  L, Pietrelli  L, ; NHLBI Retrovirus Epidemiology Study (REDS). The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion. 2005;45:469–79. DOIPubMedGoogle Scholar
  15. Busch  MP, Caglioti  S, Robertson  EF, McAuley  JD, Tobler  LH, Kamel  H, Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med. 2005;353:460–7. DOIPubMedGoogle Scholar
  16. Stramer  SL, Fang  CT, Foster  GA, Wagner  AG, Brodsky  JP, Dodd  RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451–9. DOIPubMedGoogle Scholar
  17. Custer  BS, Tomasulo  PA, Murphy  EL, Caglioti  S, Harpool  D, McEvoy  P, Triggers for switching from minipool testing by nucleic acid technology to individual donation nucleic acid testing for West Nile virus: analysis of 2003 data to inform 2004 decision making. Transfusion. 2004;44:1547–54. DOIPubMedGoogle Scholar
  18. Busch  MP, Tobler  LH, Saldanha  J, Caglioti  S, Shyamala  V, Linnen  JM, Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. Transfusion. 2005;45:492–9. DOIPubMedGoogle Scholar
  19. SAS Institute Inc. SAS proprietary software release 8.2. Cary (NC): The Institute; 2006.
  20. Pratt  JW, Gibbons  JD. Concepts of nonparametric theory. New York: Springer-Verlag; 1981. p. 41–4.
  21. Miller  RG. Survival analysis. New York: John Wiley & Sons; 1981. p. 25–7.
  22. US Census Bureau. State and county quickfacts. [cited 2004 Sep 24]. Available from http://quickfacts.census.gov/qfd
  23. Centers for Disease Control and Prevention. Statistics, surveillance, and control: 2003 West Nile virus activity in the United States (reported as of May 21, 2004). [cited 2004 Sep 24]. Available from: http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount03_detailed.htm
  24. Centers for Disease Control and Prevention. Update: West Nile Virus screening of blood donations and transfusion-associated transmission—United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:281–4.PubMedGoogle Scholar
  25. Southam  CM, Moore  AE. Induced virus infections in man by the Egypt isolates of West Nile virus. Am J Trop Med Hyg. 1954;3:19–50.PubMedGoogle Scholar
  26. Orton  SL, Stramer  SL, Dodd  RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion. 2005;45:272–7.PubMedGoogle Scholar
  27. Martin  DA, Biggerstaff  BJ, Allen  B, Johnson  AJ, Lanciotti  RS, Roehrig  JT. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol. 2002;9:544–9.PubMedGoogle Scholar
  28. Tardei  G, Ruta  S, Chitu  V, Rossi  C, Tsai  TF, Cernescu  C. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile virus infection. J Clin Microbiol. 2000;38:2232–9.PubMedGoogle Scholar
  29. Roehrig  JT, Nash  D, Maldin  B, Labowitz  A, Martin  DA, Lanciotti  RS, Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376–9.PubMedGoogle Scholar
  30. Prince  HE, Hogrefe  WR. Detection of West Nile Virus (WNV)-specific immunoglobulin M in a reference laboratory setting during the 2002 WNV season in the United States. Clin Diagn Lab Immunol. 2003;10:764–8.PubMedGoogle Scholar
  31. Prince  HE, Tobler  LH, Lape-Nixon  M, Foster  GA, Stramer  SL, Busch  MP. Development and persistence of West Nile virus immunoglobulin M (IgM), IgA, and IgG during follow-up of viremic blood donors. J Clin Microbiol. 2005;43:4316–20. DOIPubMedGoogle Scholar

Main Article

Page created: January 27, 2012
Page updated: January 27, 2012
Page reviewed: January 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external